Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (221-230 of 293) with videos related to

Pageof 30
Sort By:
Blood|March 3, 2012
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P Leonard, Ann S LaCasce, Mitchell R Smith, et al.
Leukemia|August 26, 2024
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemiaJoost B Koedijk, Inge van der Werf, Livius Penter, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2011
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1Wenchu Lin, Jian Cao, Jiayun Liu, et al.
JAMA Oncology|August 28, 2020
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical TrialJonathan D Schoenfeld, Glenn J Hanna, Vickie Y Jo, et al.
Blood Advances|July 24, 2025
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell LymphomaNira Krasnow, Katie Maurer, Catherine Jiawen Song, et al.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Cancer Cell|June 12, 2019
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid TumorsDenarda Dangaj, Marine Bruand, Alizée J Grimm, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2017
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression StatusTsuyoshi Hamada, Yin Cao, Zhi Rong Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Pageof 30

Showing results (221-230 of 293) with videos related to

Sort By:
Pageof 30
Blood|March 3, 2012
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P Leonard, Ann S LaCasce, Mitchell R Smith, et al.
Leukemia|August 26, 2024
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemiaJoost B Koedijk, Inge van der Werf, Livius Penter, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2011
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1Wenchu Lin, Jian Cao, Jiayun Liu, et al.
JAMA Oncology|August 28, 2020
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical TrialJonathan D Schoenfeld, Glenn J Hanna, Vickie Y Jo, et al.
Blood Advances|July 24, 2025
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell LymphomaNira Krasnow, Katie Maurer, Catherine Jiawen Song, et al.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Cancer Cell|June 12, 2019
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid TumorsDenarda Dangaj, Marine Bruand, Alizée J Grimm, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2017
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression StatusTsuyoshi Hamada, Yin Cao, Zhi Rong Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Pageof 30